Tolerance of one-month intranasal interferon
Under double‐blind conditions, groups of volunteers (68 in total) were allocated at random to take intranasal solutions of placebo or one of three doses of highly purified leucocyte interferon by intranasal spray twice a day for 28 days. The highest dose would have been expected to protect against e...
Gespeichert in:
| Veröffentlicht in: | Journal of medical virology 1985-10, Vol.17 (2), p.99-106 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 106 |
|---|---|
| container_issue | 2 |
| container_start_page | 99 |
| container_title | Journal of medical virology |
| container_volume | 17 |
| creator | Scott, G. M. Onwubalili, J. K. Robinson, J. A. Doré, C. Secher, D. S. Cantell, K. |
| description | Under double‐blind conditions, groups of volunteers (68 in total) were allocated at random to take intranasal solutions of placebo or one of three doses of highly purified leucocyte interferon by intranasal spray twice a day for 28 days. The highest dose would have been expected to protect against experimental colds. Treatment was discontinued because of upper respiratory symptoms as often in each of the interferon groups as in the placebo group. However, it was possible to distinguish clinically between “colds” on placebo and low‐dose interferon and “reactions to treatment” on high‐dose interferon. The features of the reactions to treatment were a protracted build‐up of local symptoms and minor epistaxis. None of the volunteers on the high‐dose interferon were thought to have a definite cold, but viruses were isolated from four out of six volunteers on low‐dose interferon who had definite colds. Previous experiments had also shown this dose to be insufficient to protect against experimental rhinovirus challenge.
The dose of interferon that appeared to protect against virus infection caused significant unwanted effects. It is essential to find interferon preparations with less inflammatory activity before interferon can be considered for use as a long‐term prophylactic against the common cold. |
| doi_str_mv | 10.1002/jmv.1890170202 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7166573</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>14267408</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5332-a33bba04584f04b419568708396a8698a373ff359a29c649febb938b02f3e8be3</originalsourceid><addsrcrecordid>eNqFUMlOwzAQtRAISuHKDakHxImUsZ14uSAhlhZEy4XlaDlhDIEkBrtl-XtStSpw4jSjecs8PUJ2KPQpADt8rt_7VGmgEhiwFdKhoEWiQdJV0gGaikQImm2QzRifAUBpxtbJOtNaciU75ODGVxhsU2DPu55vMKl9M3nqlc2kvdpoq9mKwWHwzRZZc7aKuL2YXXJ7fnZzMkyurgcXJ8dXSZFxzhLLeZ5bSDOVOkjzlOpMKAmKa2GV0MpyyZ3jmbZMFyLVDvNcc5UDcxxVjrxLjua-r9O8xocCZ2Eq8xrK2oYv421p_iJN-WQe_buRVIhM8tZgf2EQ_NsU48TUZSywqmyDfhoNTZmQaZuoS_pzYhF8jAHd8gkFM-vXtP2an35bwe7vaEv6otAW31vgNha2crNqy7ikSS0UV6Kl6Tnto6zw65-n5nJ09ydCMteWcYKfS60NL0ZILjNzPx6Y4Xg0PFXjewP8G3Pior0</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>14267408</pqid></control><display><type>article</type><title>Tolerance of one-month intranasal interferon</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Scott, G. M. ; Onwubalili, J. K. ; Robinson, J. A. ; Doré, C. ; Secher, D. S. ; Cantell, K.</creator><creatorcontrib>Scott, G. M. ; Onwubalili, J. K. ; Robinson, J. A. ; Doré, C. ; Secher, D. S. ; Cantell, K.</creatorcontrib><description>Under double‐blind conditions, groups of volunteers (68 in total) were allocated at random to take intranasal solutions of placebo or one of three doses of highly purified leucocyte interferon by intranasal spray twice a day for 28 days. The highest dose would have been expected to protect against experimental colds. Treatment was discontinued because of upper respiratory symptoms as often in each of the interferon groups as in the placebo group. However, it was possible to distinguish clinically between “colds” on placebo and low‐dose interferon and “reactions to treatment” on high‐dose interferon. The features of the reactions to treatment were a protracted build‐up of local symptoms and minor epistaxis. None of the volunteers on the high‐dose interferon were thought to have a definite cold, but viruses were isolated from four out of six volunteers on low‐dose interferon who had definite colds. Previous experiments had also shown this dose to be insufficient to protect against experimental rhinovirus challenge.
The dose of interferon that appeared to protect against virus infection caused significant unwanted effects. It is essential to find interferon preparations with less inflammatory activity before interferon can be considered for use as a long‐term prophylactic against the common cold.</description><identifier>ISSN: 0146-6615</identifier><identifier>EISSN: 1096-9071</identifier><identifier>DOI: 10.1002/jmv.1890170202</identifier><identifier>PMID: 2997387</identifier><identifier>CODEN: JMVIDB</identifier><language>eng</language><publisher>New York: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>Administration, Intranasal ; Adolescent ; Adult ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Antiviral agents ; Biological and medical sciences ; coronavirus ; Double-Blind Method ; Drug Evaluation ; Drug Tolerance ; Female ; Humans ; Interferon Inducers ; Interferon Type I - administration & dosage ; Interferon Type I - toxicity ; leucocyte interferon ; Male ; Medical sciences ; Middle Aged ; Parainfluenza Virus 1, Human - immunology ; paramyxovirus ; Pharmacology. Drug treatments ; Respiratory Tract Diseases - chemically induced ; rhinovirus ; volunteers</subject><ispartof>Journal of medical virology, 1985-10, Vol.17 (2), p.99-106</ispartof><rights>Copyright © 1985 Wiley‐Liss, Inc., A Wiley Company</rights><rights>1987 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5332-a33bba04584f04b419568708396a8698a373ff359a29c649febb938b02f3e8be3</citedby><cites>FETCH-LOGICAL-c5332-a33bba04584f04b419568708396a8698a373ff359a29c649febb938b02f3e8be3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fjmv.1890170202$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fjmv.1890170202$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>230,314,776,780,881,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=7968386$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/2997387$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Scott, G. M.</creatorcontrib><creatorcontrib>Onwubalili, J. K.</creatorcontrib><creatorcontrib>Robinson, J. A.</creatorcontrib><creatorcontrib>Doré, C.</creatorcontrib><creatorcontrib>Secher, D. S.</creatorcontrib><creatorcontrib>Cantell, K.</creatorcontrib><title>Tolerance of one-month intranasal interferon</title><title>Journal of medical virology</title><addtitle>J. Med. Virol</addtitle><description>Under double‐blind conditions, groups of volunteers (68 in total) were allocated at random to take intranasal solutions of placebo or one of three doses of highly purified leucocyte interferon by intranasal spray twice a day for 28 days. The highest dose would have been expected to protect against experimental colds. Treatment was discontinued because of upper respiratory symptoms as often in each of the interferon groups as in the placebo group. However, it was possible to distinguish clinically between “colds” on placebo and low‐dose interferon and “reactions to treatment” on high‐dose interferon. The features of the reactions to treatment were a protracted build‐up of local symptoms and minor epistaxis. None of the volunteers on the high‐dose interferon were thought to have a definite cold, but viruses were isolated from four out of six volunteers on low‐dose interferon who had definite colds. Previous experiments had also shown this dose to be insufficient to protect against experimental rhinovirus challenge.
The dose of interferon that appeared to protect against virus infection caused significant unwanted effects. It is essential to find interferon preparations with less inflammatory activity before interferon can be considered for use as a long‐term prophylactic against the common cold.</description><subject>Administration, Intranasal</subject><subject>Adolescent</subject><subject>Adult</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Antiviral agents</subject><subject>Biological and medical sciences</subject><subject>coronavirus</subject><subject>Double-Blind Method</subject><subject>Drug Evaluation</subject><subject>Drug Tolerance</subject><subject>Female</subject><subject>Humans</subject><subject>Interferon Inducers</subject><subject>Interferon Type I - administration & dosage</subject><subject>Interferon Type I - toxicity</subject><subject>leucocyte interferon</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Parainfluenza Virus 1, Human - immunology</subject><subject>paramyxovirus</subject><subject>Pharmacology. Drug treatments</subject><subject>Respiratory Tract Diseases - chemically induced</subject><subject>rhinovirus</subject><subject>volunteers</subject><issn>0146-6615</issn><issn>1096-9071</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1985</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFUMlOwzAQtRAISuHKDakHxImUsZ14uSAhlhZEy4XlaDlhDIEkBrtl-XtStSpw4jSjecs8PUJ2KPQpADt8rt_7VGmgEhiwFdKhoEWiQdJV0gGaikQImm2QzRifAUBpxtbJOtNaciU75ODGVxhsU2DPu55vMKl9M3nqlc2kvdpoq9mKwWHwzRZZc7aKuL2YXXJ7fnZzMkyurgcXJ8dXSZFxzhLLeZ5bSDOVOkjzlOpMKAmKa2GV0MpyyZ3jmbZMFyLVDvNcc5UDcxxVjrxLjua-r9O8xocCZ2Eq8xrK2oYv421p_iJN-WQe_buRVIhM8tZgf2EQ_NsU48TUZSywqmyDfhoNTZmQaZuoS_pzYhF8jAHd8gkFM-vXtP2an35bwe7vaEv6otAW31vgNha2crNqy7ikSS0UV6Kl6Tnto6zw65-n5nJ09ydCMteWcYKfS60NL0ZILjNzPx6Y4Xg0PFXjewP8G3Pior0</recordid><startdate>198510</startdate><enddate>198510</enddate><creator>Scott, G. M.</creator><creator>Onwubalili, J. K.</creator><creator>Robinson, J. A.</creator><creator>Doré, C.</creator><creator>Secher, D. S.</creator><creator>Cantell, K.</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><general>Wiley-Liss</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7U9</scope><scope>H94</scope><scope>5PM</scope></search><sort><creationdate>198510</creationdate><title>Tolerance of one-month intranasal interferon</title><author>Scott, G. M. ; Onwubalili, J. K. ; Robinson, J. A. ; Doré, C. ; Secher, D. S. ; Cantell, K.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5332-a33bba04584f04b419568708396a8698a373ff359a29c649febb938b02f3e8be3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1985</creationdate><topic>Administration, Intranasal</topic><topic>Adolescent</topic><topic>Adult</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Antiviral agents</topic><topic>Biological and medical sciences</topic><topic>coronavirus</topic><topic>Double-Blind Method</topic><topic>Drug Evaluation</topic><topic>Drug Tolerance</topic><topic>Female</topic><topic>Humans</topic><topic>Interferon Inducers</topic><topic>Interferon Type I - administration & dosage</topic><topic>Interferon Type I - toxicity</topic><topic>leucocyte interferon</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Parainfluenza Virus 1, Human - immunology</topic><topic>paramyxovirus</topic><topic>Pharmacology. Drug treatments</topic><topic>Respiratory Tract Diseases - chemically induced</topic><topic>rhinovirus</topic><topic>volunteers</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Scott, G. M.</creatorcontrib><creatorcontrib>Onwubalili, J. K.</creatorcontrib><creatorcontrib>Robinson, J. A.</creatorcontrib><creatorcontrib>Doré, C.</creatorcontrib><creatorcontrib>Secher, D. S.</creatorcontrib><creatorcontrib>Cantell, K.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of medical virology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Scott, G. M.</au><au>Onwubalili, J. K.</au><au>Robinson, J. A.</au><au>Doré, C.</au><au>Secher, D. S.</au><au>Cantell, K.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Tolerance of one-month intranasal interferon</atitle><jtitle>Journal of medical virology</jtitle><addtitle>J. Med. Virol</addtitle><date>1985-10</date><risdate>1985</risdate><volume>17</volume><issue>2</issue><spage>99</spage><epage>106</epage><pages>99-106</pages><issn>0146-6615</issn><eissn>1096-9071</eissn><coden>JMVIDB</coden><abstract>Under double‐blind conditions, groups of volunteers (68 in total) were allocated at random to take intranasal solutions of placebo or one of three doses of highly purified leucocyte interferon by intranasal spray twice a day for 28 days. The highest dose would have been expected to protect against experimental colds. Treatment was discontinued because of upper respiratory symptoms as often in each of the interferon groups as in the placebo group. However, it was possible to distinguish clinically between “colds” on placebo and low‐dose interferon and “reactions to treatment” on high‐dose interferon. The features of the reactions to treatment were a protracted build‐up of local symptoms and minor epistaxis. None of the volunteers on the high‐dose interferon were thought to have a definite cold, but viruses were isolated from four out of six volunteers on low‐dose interferon who had definite colds. Previous experiments had also shown this dose to be insufficient to protect against experimental rhinovirus challenge.
The dose of interferon that appeared to protect against virus infection caused significant unwanted effects. It is essential to find interferon preparations with less inflammatory activity before interferon can be considered for use as a long‐term prophylactic against the common cold.</abstract><cop>New York</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><pmid>2997387</pmid><doi>10.1002/jmv.1890170202</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0146-6615 |
| ispartof | Journal of medical virology, 1985-10, Vol.17 (2), p.99-106 |
| issn | 0146-6615 1096-9071 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7166573 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Administration, Intranasal Adolescent Adult Antibiotics. Antiinfectious agents. Antiparasitic agents Antiviral agents Biological and medical sciences coronavirus Double-Blind Method Drug Evaluation Drug Tolerance Female Humans Interferon Inducers Interferon Type I - administration & dosage Interferon Type I - toxicity leucocyte interferon Male Medical sciences Middle Aged Parainfluenza Virus 1, Human - immunology paramyxovirus Pharmacology. Drug treatments Respiratory Tract Diseases - chemically induced rhinovirus volunteers |
| title | Tolerance of one-month intranasal interferon |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-06T23%3A01%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Tolerance%20of%20one-month%20intranasal%20interferon&rft.jtitle=Journal%20of%20medical%20virology&rft.au=Scott,%20G.%20M.&rft.date=1985-10&rft.volume=17&rft.issue=2&rft.spage=99&rft.epage=106&rft.pages=99-106&rft.issn=0146-6615&rft.eissn=1096-9071&rft.coden=JMVIDB&rft_id=info:doi/10.1002/jmv.1890170202&rft_dat=%3Cproquest_pubme%3E14267408%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=14267408&rft_id=info:pmid/2997387&rfr_iscdi=true |